A review of the therapeutic potential of histone deacetylase inhibitors in rhabdomyosarcoma

By sjmartinez • September 4, 2023

Selim O, Song C, Kumar A, Phelan R, Singh A, Federman N. A review of the therapeutic potential of histone deacetylase inhibitors in rhabdomyosarcoma. Front Oncol. 2023 Aug 18;13:1244035. doi: 10.3389/fonc.2023.1244035. PMID: 37664028; PMCID: PMC10471891.

Tags: clinical trials, Hematology/Oncology, histone deacetylase inhibitors, mutations, pediatric cancer, Publications, rhabdomyosarcoma

Utilizing natural language processing (NLP) to identify breast cancer-associated lung metastases from pathology reports to delineate characteristics of this site of recurrence

López JCV, Ho A, Hughes KS, Bardia A, Vidula N. Utilizing natural language processing (NLP) to identify breast cancer-associated lung metastases from pathology reports to[...]

Plain language summary of the LOGIC 2 study: Encorafenib, binimetinib, plus a third drug for people with BRAF V600-mutant melanoma

Dummer R, Sandhu S, Miller WH Jr, Butler MO, Taylor MH, Heinzerling L, Blank CU, Couselo EM, Burris HA 3rd, Postow MA, Chmielowski B, Middleton[...]

BASECAMP-1 screening study: a model for efficient enrolment in precision oncology clinical trials

Hecht JR, Molina JR, Liechty K, Welling TH, Grierson PM, Patel SP, Kirtane K, Morelli MP, Locke FL, Maloney DG, Punekar SR, Nikiforow S, Lin[...]